Edwards Lifesciences Corporation · NYSE:EW

Edwards Lifesciences — Shareholder Meeting (March 2025)

13 slides from Edwards Lifesciences's shareholder meeting presentation, Mar 26, 2025

  1. Slide 1: Schedule 14A Proxy Statement

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy

  2. Slide 2: Edwards Lifesciences Spring 2025 Stockholder Presentation

    Edwards Lifesciences Spring 2025 Stockholder Presentation

  3. Slide 3: Cautionary Statement and Use of Non-GAAP Financial Measures

    Cautionary Statement and Use of Non-GAAP Financial Measures 2 This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statement

  4. Slide 4: We Request Your Support at the 2025 Annual Meeting of Stockholders

    We Request Your Support at the 2025 Annual Meeting of Stockholders 3 Proposal 1. FOR Election of Nine Director Nominees Proposal 2. FOR Advisory Vote to Approve Named Executive Officer Compensation Proposal 3. FOR Ratification of Appointment of Independent Registered Public Accounting Firm Proposal

  5. Slide 5: Our Credo

    At Edwards Lifesciences, we are dedicated to providing innovative solutions for people fighting cardiovascular disease. Through our actions, we will become trusted partners with customers, colleagues, and patients – creating a community unified in its mission to improve the quality of life around th

  6. Slide 6: Built to Innovate and Transform Lives

    5 Built to Innovate and Transform Lives Elevating the standard of care for millions of patients Corporate impact is integrated with our strategy 24 years of strong financial performance since IPO 16,000+ employees dedicated to helping patients Global scale and reach supporting patients in 100 countr

  7. Slide 7: Our Innovation Strategy

    6 Our Innovation Strategy Long-term commitment Risk-taking and agility Leading with science 10,000+ patents 1,000+ publications including 10 publications of FDA- approved studies in NEJM Deep stakeholder relationships Pioneering breakthroughs ~95% of Edwards’ technologies are category-leading Lifeti

  8. Slide 8: Our Expansion within Structural Heart Results in Diversified Sources of Growth

    Tricuspid TMTT Mitral TAVR Aortic Stenosis Foundation of consistent growth and leadership Our Expansion within Structural Heart Results in Diversified Sources of Growth SIGNIFICANT EMERGING OPPORTUNITIES TAVR-AR Aortic Regurgitation Structural Heart Failure Implantable Heart Failure Management Addit

  9. Slide 9: Well-Qualified Board with Broad Expertise

    Well-Qualified Board with Broad Expertise 8 Provides valuable insights and direction to our Board gained through extensive executive management experience at medical technology companies Brings global manufacturing and operational experience in highly regulated industries and experience leading larg

  10. Slide 10: Board Skills Tied to Innovation Strategy

    Board Skills Tied to Innovation Strategy 9 Medical Technology Industry Experience International Executive Experience Corporate Governance Risk Management Risk Oversight Executive Leadership Innovation and Technology Corporate Impact and Corporate Responsibility Operations Management Corporate Strate

  11. Slide 11: CEO Pay Elements and Performance Measures

    18% 15% 33% 17% 17% CEO Pay Element Components Corporate Performance Measures & Rationale Base Salary Cash  Attract and retain executives Annual Cash Incentive(1) Financial Measurement  Based on underlying revenue growth (50%), adjusted earnings per share (30%), and adjusted free cash flow (20%) t

  12. Slide 12: Commitment to Stockholder Engagement

    11 Commitment to Stockholder Engagement We have consistently contacted stockholders holding >50% of outstanding stock each year since 2015 to discuss topics of interest with active participation from an independent director 20 25 20 15 DISCUSSION TOPICS Governance features and stockholder rights Boa

  13. Slide 13: Slide 13

Edwards Lifesciences — Shareholder Meeting (March 2025) on 6ix